Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE trial of neoadjuvant nivolumab with or without ipilimumab in resectable cutaneous squamous cell carcinoma
NL-OMON52693Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Histopathological tumor response in resection specimen. Started Aug 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NL-OMON52693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52693.